Statistical characteristics of moxifloxacin-induced QTc effect
- PMID: 20358432
- DOI: 10.1080/10543400903581945
Statistical characteristics of moxifloxacin-induced QTc effect
Abstract
Moxifloxacin has been the most commonly used positive control in "thorough" QTc (TQT) studies. In a TQT study, the assay sensitivity is often considered to be established if the baseline corrected mean difference in QTc between moxifloxacin and placebo is greater than 5 ms in common practice at one or more prespecified time points and the observed moxifloxacin induced QTc effect over time follows the proper pharmacokinetics profile. To better understand the statistical characteristics of moxifloxacin-induced QTc prolongation and to provide guidance for future studies, 20 TQT studies that involved moxifloxacin have been evaluated. We study the QTc profile of the baseline adjusted mean difference in QTc between moxifloxacin and placebo over time. Zhang (2008) proposed that the moxifloxacin induced QTc effect can be evaluated between 1 and 4 h after a single dose (400 mg) administration near the time (T(max)) of peak concentration instead of all time points (typically 9-12 time points) at which QT was measured for the study drug evaluation. After evaluating 20 TQT studies, we confirm that the maximum moxifloxacin effect occurs in the time window between 1 and 4 h post dose. We also investigate the variability of the data as well as correlations between time points and between regimens. These findings and results can be used as a reference for future studies.
Similar articles
-
Statistical consideration in testing for assay sensitivity in a "thorough" QT study.J Biopharm Stat. 2010 May;20(3):641-53. doi: 10.1080/10543400903582042. J Biopharm Stat. 2010. PMID: 20358442
-
Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.Int J Clin Pharmacol Ther. 2012 Aug;50(8):595-604. doi: 10.5414/CP201693. Int J Clin Pharmacol Ther. 2012. PMID: 22735462 Clinical Trial.
-
Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.Clin Ther. 2008 Feb;30(2):260-70. doi: 10.1016/j.clinthera.2008.02.002. Clin Ther. 2008. PMID: 18343264 Clinical Trial.
-
Multiple comparisons of repeated measured response: issues of assessment of prolongation of QT interval in thorough QT trials.J Biopharm Stat. 2010 May;20(3):604-14. doi: 10.1080/10543400903582034. J Biopharm Stat. 2010. PMID: 20358439 Review.
-
Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.Clin Ther. 2004 Jul;26(7):940-50. doi: 10.1016/s0149-2918(04)90170-1. Clin Ther. 2004. PMID: 15336463 Review.
Cited by
-
No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.Antimicrob Agents Chemother. 2012 May;56(5):2408-13. doi: 10.1128/AAC.05194-11. Epub 2012 Feb 27. Antimicrob Agents Chemother. 2012. PMID: 22371898 Free PMC article. Clinical Trial.
-
Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study.Br J Clin Pharmacol. 2015 Sep;80(3):446-59. doi: 10.1111/bcp.12684. Epub 2015 Jul 2. Br J Clin Pharmacol. 2015. PMID: 26011050 Free PMC article. Clinical Trial.
-
The effects of moxifloxacin on QTc interval in healthy Korean male subjects.Drugs R D. 2014 Jun;14(2):63-71. doi: 10.1007/s40268-014-0040-1. Drugs R D. 2014. PMID: 24691742 Free PMC article. Clinical Trial.
-
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects.Clin Pharmacol Drug Dev. 2022 Apr;11(4):442-453. doi: 10.1002/cpdd.1056. Epub 2022 Feb 19. Clin Pharmacol Drug Dev. 2022. PMID: 35182043 Free PMC article. Clinical Trial.
-
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.Cancer Chemother Pharmacol. 2013 Mar;71(3):565-73. doi: 10.1007/s00280-012-2030-8. Epub 2013 Jan 24. Cancer Chemother Pharmacol. 2013. PMID: 23344712 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical